SG93251A1 - 1,2,4,5-tetrahydro-benzo[d]azepines - Google Patents

1,2,4,5-tetrahydro-benzo[d]azepines

Info

Publication number: SG93251A1
Authority: SG; Singapore
Prior art keywords: azepines; benzo; tetrahydro
Prior art date: 1999-08-06

Application number

SG200004344A

Other languages

English (en)

Inventor

Adam Geo

Binggeli Alfred

Marki Hans-Peter

Mutel Vincent

Wilhelm Maurice

Wostl Wolfgang

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-08-02

Publication date

2002-12-17

2000-08-02 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2002-12-17 Publication of SG93251A1 publication Critical patent/SG93251A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

SG200004344A 1999-08-06 2000-08-02 1,2,4,5-tetrahydro-benzo[d]azepines SG93251A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99115557		1999-08-06

Publications (1)

Publication Number	Publication Date
SG93251A1 true SG93251A1 (en)	2002-12-17

Family

ID=8238742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200004344A SG93251A1 (en)	1999-08-06	2000-08-02	1,2,4,5-tetrahydro-benzo[d]azepines

Country Status (27)

Country	Link
US (1)	US6218385B1 (es)
JP (1)	JP3260350B2 (es)
KR (1)	KR100390116B1 (es)
CN (1)	CN1146455C (es)
AR (1)	AR025035A1 (es)
AT (1)	ATE254614T1 (es)
AU (1)	AU774485B2 (es)
BR (1)	BR0003375A (es)
CA (1)	CA2314798A1 (es)
CO (1)	CO5180625A1 (es)
DE (1)	DE60006618T2 (es)
ES (1)	ES2209728T3 (es)
HR (1)	HRP20000520A2 (es)
HU (1)	HUP0003112A3 (es)
ID (1)	ID26743A (es)
IL (1)	IL137688A0 (es)
MA (1)	MA26748A1 (es)
NO (1)	NO20003966L (es)
NZ (1)	NZ506096A (es)
PE (1)	PE20010467A1 (es)
PL (1)	PL341890A1 (es)
RU (1)	RU2240317C2 (es)
SG (1)	SG93251A1 (es)
TR (1)	TR200002298A3 (es)
UY (1)	UY26276A1 (es)
YU (1)	YU49700A (es)
ZA (1)	ZA200003927B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1345609E (pt) *	2000-12-22	2005-08-31	Hoffmann La Roche	Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
KR100765027B1 (ko) *	2002-12-20	2007-10-09	글락소 그룹 리미티드	신경 장애 치료용 벤즈아제핀 유도체
JP4782003B2 (ja) *	2003-06-17	2011-09-28	アリーナファーマシューティカルズ，インコーポレイテッド	５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
EP2189448B1 (en)	2003-06-17	2014-01-29	Arena Pharmaceuticals, Inc.	Processes for the Separation of 3-Benzazepine Racemates
US20080009478A1 (en) *	2003-10-22	2008-01-10	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
WO2005042490A1 (en) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1838677T1 (sl)	2004-12-21	2010-01-29	Arena Pharm Inc	Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
AU2005322183B2 (en)	2004-12-23	2012-03-29	Arena Pharmaceuticals, Inc.	5HT2C receptor modulator compositions and methods of use
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP1942879A1 (en)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP5199997B2 (ja) *	2006-04-03	2013-05-15	アリーナファーマシューティカルズ，インコーポレイテッド	８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
EP1873527A1 (en) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Method for identifying CRMP modulators
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2610508T3 (es)	2006-11-22	2017-04-27	Clinical Research Associates, Llc	Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
ES2522587T3 (es) *	2006-12-05	2014-11-17	Arena Pharmaceuticals, Inc.	Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
TW200845978A (en) *	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2288585A1 (en)	2008-03-04	2011-03-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102648170A (zh)	2009-06-18	2012-08-22	艾尼纳制药公司	制备5-ht2c受体激动剂的方法
EP2544688B1 (en)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Methods and compositions for treatment of angelman syndrome
US20110294879A1 (en)	2010-05-28	2011-12-01	Xenoport, Inc.	Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US9045431B2 (en)	2010-06-02	2015-06-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
CN103347523A (zh)	2010-09-01	2013-10-09	艾尼纳制药公司	向具有肾损伤的个体给药氯卡色林
EP2611782A1 (en)	2010-09-01	2013-07-10	Arena Pharmaceuticals, Inc.	Salts of lorcaserin with optically active acids
KR20130101524A (ko)	2010-09-01	2013-09-13	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
CN103189053A (zh)	2010-09-01	2013-07-03	艾尼纳制药公司	用于体重控制的5-ht2c激动剂的调节释放剂型
CA2886875A1 (en)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
US5444062A (en) *	1990-11-06	1995-08-22	Pfizer Inc.	Quinazolines derivatives for enhancing antitumor activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU678503B2 (en) *	1993-09-24	1997-05-29	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

2000
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/en not_active Abandoned
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-04 TR TR2000/02298A patent/TR200002298A3/tr unknown
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
US5444062A (en) *	1990-11-06	1995-08-22	Pfizer Inc.	Quinazolines derivatives for enhancing antitumor activity
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number	Publication date
UY26276A1 (es)	2000-10-31
JP3260350B2 (ja)	2002-02-25
DE60006618T2 (de)	2004-09-23
ZA200003927B (en)	2001-02-06
ES2209728T3 (es)	2004-07-01
HUP0003112A3 (en)	2003-07-28
AU774485B2 (en)	2004-07-01
US6218385B1 (en)	2001-04-17
YU49700A (sh)	2003-04-30
TR200002298A2 (tr)	2001-03-21
IL137688A0 (en)	2001-10-31
BR0003375A (pt)	2001-03-13
TR200002298A3 (tr)	2001-03-21
KR20010082510A (ko)	2001-08-30
HUP0003112A2 (hu)	2002-11-28
HRP20000520A2 (en)	2001-06-30
CN1283623A (zh)	2001-02-14
ATE254614T1 (de)	2003-12-15
CO5180625A1 (es)	2002-07-30
PL341890A1 (en)	2001-02-12
KR100390116B1 (ko)	2003-07-04
RU2240317C2 (ru)	2004-11-20
HU0003112D0 (en)	2000-10-28
NO20003966L (no)	2001-02-07
ID26743A (id)	2001-02-08
PE20010467A1 (es)	2001-04-17
DE60006618D1 (de)	2003-12-24
NZ506096A (en)	2002-08-28
JP2001089472A (ja)	2001-04-03
AR025035A1 (es)	2002-11-06
AU4897900A (en)	2001-02-08
CN1146455C (zh)	2004-04-21
CA2314798A1 (en)	2001-02-06
NO20003966D0 (no)	2000-08-04
MA26748A1 (fr)	2004-12-20

Publication	Publication Date	Title
IL137688A0 (en)	2001-10-31	1,2,4,5- tetrahydro-benzo [d] azepines
EP1180085A4 (en)	2004-09-29	SPIN VALVE
ZA200204863B (en)	2003-03-17	Suspension comprising oxcarbazepine.
PL350864A1 (en)	2003-02-10	5-ht1f
ZA200108481B (en)	2003-03-26	8A- and 9A-15-membered lactams.
GB9923730D0 (en)	1999-12-08	Bag making
GB9923725D0 (en)	1999-12-08	Bag making
MXPA02005070A (es)	2003-09-25	1-benzazepinas sustituidas y derivados de las mismas.
IL132619A0 (en)	2001-03-19	Linked lists
AU3630300A (en)	2000-10-09	Papermaker's yarn
IL146124A0 (en)	2002-07-25	1,5-benzodiazepine derivatives
GC0000195A (en)	2006-03-29	Benzoamido- and thiophenecarboxyamido-1,2,3,4-tetrahydroisoquinol-7-ine compunds as anticonvulsant agents
HUP9902291A2 (hu)	2001-12-28	Új 2,3-benzodiazepin-származékok
GB9923726D0 (en)	1999-12-08	Bag making
GB9823972D0 (en)	1998-12-30	Hosiery
ZA200107384B (en)	2002-09-18	Spinneret.
GB9910366D0 (en)	1999-06-30	1,5-Benzodiazepine Derivatives
AU3196000A (en)	2000-10-04	3,3'-diketotrehalose
GB2350361B (en)	2003-12-03	3,4,5-tricyanophenyl derivatives
GB9803233D0 (en)	1998-04-08	Letterbox
HUP0203381A3 (en)	2003-04-28	5-halo-4-fluoro-4,7,7-trimethyl-3-oxabicyclo[4.1.0]heptane-2-on
EG23327A (en)	2004-12-29	Metraplant "iucd".
SI1239832T1 (en)	2004-10-31	Suspension comprising oxcarbazepine
IL165436A0 (en)	2006-01-15	7,10-bis-trichlotoacetyl-10 deactylbaccatin III
CA85870S (en)	1999-02-19	Deodorizing bar